二甲双胍与安慰剂对乳腺癌患者浸润性疾病无生存期的影响:MA.32随机临床试验
MA.32是一项在加拿大、瑞士、美国和英国开展的3期随机、安慰剂对照、双盲试验,纳入3649例接受标准治疗的高风险非转移性乳腺癌患者,随机接受口服二甲双胍850 mg每日两次或安慰剂每日两次,持续5年。在激素受体阳性患者中,二甲双胍组与安慰剂组的浸润性疾病无生存期事件发生率分别为每100患者年2.78 vs 2.74(HR 1.01,95%CI 0.84-1.21,P=0.93),无显著改善。
要点
- 在高风险可手术乳腺癌非糖尿病患者中,二甲双胍对比安慰剂未显著改善浸润性疾病无生存期。
- 激素受体阳性患者中,二甲双胍组与安慰剂组的浸润性疾病无生存期事件发生率分别为每100患者年2.78 vs 2.74(HR 1.01,95%CI 0.84-1.21,P=0.93)。
- 二甲双胍组3级非血液学毒性事件发生率高于安慰剂组(21.5% vs 17.5%,P=0.003)。
核心结论
- 在高风险可手术乳腺癌非糖尿病患者中,标准乳腺癌治疗基础上加用二甲双胍对比安慰剂未显著改善浸润性疾病无生存期。
研究设计与样本
- MA.32是一项在加拿大、瑞士、美国和英国开展的3期随机、安慰剂对照、双盲试验。
- 2010年8月至2013年3月期间纳入3649例接受标准治疗的高风险非转移性乳腺癌患者,随访至2020年10月。
- 患者随机接受口服二甲双胍850 mg每日两次(n=1824)或口服安慰剂每日两次(n=1825),持续5年。
- 随机分层因素包括激素受体(雌激素受体和/或孕激素受体{ER/PgR})状态(阳性 vs 阴性)、体重指数(≤30 vs >30)、人表皮生长因子受体2(ERBB2,原HER2或HER2/neu)状态(阳性 vs 阴性)和是否接受化疗。
- 主要结局为激素受体阳性乳腺癌的浸润性疾病无生存期。
主要发现
- 3649例随机患者(平均年龄52.4岁;3643例女性[99.8%])全部(100%)纳入分析。
- 第二次中期分析后,ER/PgR阴性患者被判定为无效,因此主要分析在2533例ER/PgR阳性患者中进行。
- ER/PgR阳性组中位随访时间为96.2个月(范围0.2-121个月),共发生465例浸润性疾病无生存期事件。
- ER/PgR阳性患者中,二甲双胍组与安慰剂组的浸润性疾病无生存期事件发生率分别为每100患者年2.78 vs 2.74(HR 1.01,95%CI 0.84-1.21,P=0.93);死亡率分别为每100患者年1.46 vs 1.32(HR 1.10,95%CI 0.86-1.41,P=0.47)。
- ER/PgR阴性患者中位随访94.1个月,二甲双胍组与安慰剂组的浸润性疾病无生存期事件发生率分别为每100患者年3.58 vs 3.60(HR 1.01,95%CI 0.79-1.30,P=0.92)。
关键数值与推荐
- ER/PgR阳性患者中,二甲双胍组 vs 安慰剂组的浸润性疾病无生存期事件发生率:每100患者年2.78 vs 2.74(HR 1.01,95%CI 0.84-1.21,P=0.93)。
- ER/PgR阳性患者中,二甲双胍组 vs 安慰剂组的死亡率:每100患者年1.46 vs 1.32(HR 1.10,95%CI 0.86-1.41,P=0.47)。
- ER/PgR阴性患者中,二甲双胍组 vs 安慰剂组的浸润性疾病无生存期事件发生率:每100患者年3.58 vs 3.60(HR 1.01,95%CI 0.79-1.30,P=0.92)。
- 3级非血液学毒性事件发生率:二甲双胍组21.5% vs 安慰剂组17.5%(P=0.003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. OBJECTIVE: To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes. DESIGN, SETTING, AND PARTICIPANTS: MA.32, a phase 3 randomized, placebo-controlled, double-blind trial, conducted in Canada, Switzerland, US, and UK, enrolled 3649 patients with high-risk nonmetastatic breast cancer receiving standard therapy between August 2010 and March 2013, with follow-up to October 2020. INTERVENTIONS: Patients were randomized (stratified for hormone receptor [estrogen receptor and/or progesterone receptor {ER/PgR}] status, positive vs negative; body mass index, ≤30 vs >30; human epidermal growth factor receptor 2 [ERBB2, formerly HER2 or HER2/neu], positive vs negative; and any vs no chemotherapy) to 850 mg of oral metformin twice a day (n = 1824) or oral placebo twice a day (n = 1825) for 5 years. MAIN OUTCOMES AND MEASURES: The primary outcome was invasive disease-free survival in hormone receptor-positive breast cancer. Of the 8 secondary outcomes, overall survival, distant relapse-free survival, and breast cancer-free interval were analyzed. RESULTS: Of the 3649 randomized patients (mean age, 52.4 years; 3643 women [99.8%]), all (100%) were included in analyses. After a second interim analysis, futility was declared for patients who were ER/PgR-, so the primary analysis was conducted for 2533 patients who were ER/PgR+. The median duration of follow-up in the ER/PgR+ group was 96.2 months (range, 0.2-121 months). Invasive disease-free survival events occurred in 465 patients who were ER/PgR+. The incidence rates for invasive disease-free survival events were 2.78 per 100 patient-years in the metformin group vs 2.74 per 100 patient-years in the placebo group (hazard ratio [HR], 1.01; 95% CI, 0.84-1.21; P = .93), and the incidence rates for death were 1.46 per 100 patient-years in the metformin group vs 1.32 per 100 patient-years in the placebo group (HR, 1.10; 95% CI, 0.86-1.41; P = .47). Among patients who were ER/PgR-, followed up for a median of 94.1 months, incidence of invasive disease-free survival events was 3.58 vs 3.60 per 100 patient-years, respectively (HR, 1.01; 95% CI, 0.79-1.30; P = .92). None of the 3 secondary outcomes analyzed in the ER/PgR+ group had statistically significant differences. Grade 3 nonhematological toxic events occurred more frequently in patients taking metformin than in patients taking placebo (21.5% vs 17.5%, respectively, P = .003). The most common grade 3 or higher adverse events in the metformin vs placebo groups were hypertension (2.4% vs 1.9%), irregular menses (1.5% vs 1.4%), and diarrhea (1.9% vs 7.0%). CONCLUSIONS AND RELEVANCE: Among patients with high-risk operable breast cancer without diabetes, the addition of metformin vs placebo to standard breast cancer treatment did not significantly improve invasive disease-free survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01101438.
引用
- Goodwin PJ, Chen BE, Gelmon KA, et al. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. JAMA. 2022. PMID: 35608580. doi:10.1001/jama.2022.6147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。